Philip Morris International (PM) Earnings Date & Reports

Key Takeaways

• Adjusted diluted EPS (earnings per share) rose 15.2% year over year to $2.20, topping Wall Street's consensus estimate of roughly $2.05.
• Net revenues grew 10.4% to $11.2 billion, crossing the $11 billion mark for the first time and beating the consensus estimate of about $10.6 billion.
• Reported diluted EPS declined 7.7% to $1.80, weighed down by a non-cash impairment related to the company's RBH equity investment.
• Organic revenue growth reached 7.6%, with gross profit up 8.7% on an organic basis.
• Smoke-free products accounted for about 42% of total net revenues, led by IQOS heated tobacco and VEEV e-vapor.
• Full-year 2026 adjusted diluted EPS guidance was updated to $8.26–$8.41, reflecting currency effects only.

Earnings Context and Why It Matters

Philip Morris International (PM) is in the middle of a deliberate transformation from a traditional cigarette maker into a broader smoke-free consumer goods company. That pivot has made each quarterly earnings report a key checkpoint for investors tracking whether IQOS, ZYN, and VEEV can offset a structurally declining combustible (cigarette) business. The second quarter of 2026 carried added weight because it followed a strong first quarter and tested how the company would hold up against headwinds such as excise-driven price increases in Japan, a flavor ban in Poland, and an uneven U.S. nicotine pouch market. The results offer a direct read on pricing power, margin trajectory, and the durability of smoke-free growth.

Reported Results

Philip Morris International reported net revenues of $11.19 billion for the second quarter of 2026, a 10.4% increase on a reported basis and 7.6% on an organic basis (which excludes currency and other non-operating effects). The figure surpassed the consensus estimate of roughly $10.6 billion.

Adjusted diluted EPS came in at $2.20, up 15.2% from $1.91 a year earlier, or 13.6% excluding a favorable currency impact of $0.03 per share. That beat the consensus estimate of about $2.05. Reported diluted EPS, however, fell 7.7% to $1.80, reflecting a non-cash impairment tied to the company's RBH equity investment in Canada.

Total shipment volume increased 2.5% to 205.2 billion units. The International Smoke-Free segment grew net revenues 14.2% (11.8% organically), while International Combustibles grew 9.8% (6.4% organically). The U.S. segment saw net revenues decline 0.7% to $856 million. IQOS heated tobacco unit (HTU) adjusted in-market sales (IMS) rose 5.1%, VEEV e-vapor shipments jumped 55.1%, and ZYN U.S. shipments increased 1.8% to 2.9 billion pouches.

For guidance, the company projected third-quarter 2026 adjusted diluted EPS of $2.20 to $2.25, including an estimated $0.08 unfavorable currency impact. Full-year 2026 adjusted diluted EPS was updated to $8.26 to $8.41, down from the prior $8.36 to $8.51 range, reflecting currency only.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following earnings-driven names like Philip Morris International, it offers a practical way to surface comparable opportunities across the consumer staples and tobacco industries. Explore the AI Screener to refine your own watchlist.

Market Reaction and Investor Sentiment

Investor sentiment heading into the report was broadly constructive, with analysts citing smoke-free momentum, pricing power, and regulatory tailwinds such as the FDA's (U.S. Food and Drug Administration) Modified Risk Tobacco Product (MRTP) authorization for 20 ZYN variants. The earnings beat on both the top and bottom lines reinforced that view, though the decline in reported EPS from the RBH impairment and the slight reduction in full-year adjusted EPS guidance, driven by currency, tempered the enthusiasm. The market's interpretation has centered on the durability of IQOS and VEEV growth and whether stepped-up U.S. investment behind ZYN can convert share gains into profit.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will focus on how Philip Morris International sustains smoke-free growth while managing near-term disruptions. In Japan, the company is navigating the effects of an excise-driven price increase, while in Europe a characterizing flavor ban in Poland has weighed on IQOS adjusted in-market sales. Excluding Japan and Poland, IQOS adjusted IMS grew about 10%, underscoring the breadth of demand outside these markets.

The U.S. remains a closely watched swing factor. The company plans to accelerate investment in the second half of 2026 to support an expanded ZYN portfolio, including the launch of 1.5mg and 8mg dry variants, and to prepare for a potential IQOS ILUMA launch subject to FDA authorization. The June MRTP authorization for 20 ZYN variants could support brand positioning, though competition in the U.S. pouch category remains uneven.

On the financial side, management maintained its full-year targets for organic net revenue growth of 5% to 7% and organic operating income growth of 7% to 9%, with operating cash flow expected around $13.5 billion. Currency movements, input and energy costs tied to the Middle East conflict, and the pace of gross cost savings toward the company's $2 billion target are additional variables to watch. The third-quarter guidance of $2.20 to $2.25 in adjusted EPS, which includes an $0.08 currency headwind, will be the next concrete test of that trajectory.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations